Key Takeaways
- ATBS drives the story: The segment grew 30% in FY25 on volume, and management expects continued double-digit growth in FY26, fueled by rising ATBS intensity in oil recovery polymers.
- AO is the emerging engine: Antioxidants revenue jumped 70% in FY25 despite a tough import environment, with a clear path to 90% capacity utilization over two years from the current ~50%.
- VOPL begins its contribution: The new subsidiary is past teething issues, commercially selling MEHQ, and targeting INR100-odd crores revenue in FY26 at just 20% utilization.
- Margins are a known constant: Management reiterated its 26%-27% EBITDA margin guidance for FY26 and views this band as sustainable over a 3-5 year horizon for the B2B specialty chemical business.
- What to watch next quarter: The timeline for the next leg of capex, contingent on successful trials of 3-4 new R&D products, and the pace of AO capacity utilization ramp-up.
ATBS: The Volume Growth Anchor
- Demand mechanics: Growth is almost entirely volume-led, driven by the oil and gas sector where higher ATBS content in polymers makes oil extraction more efficient. This application is expected to rise to 40%-45% of ATBS demand, with water treatment and other uses holding at 50%-55%.
- Capacity expansion on track: Phase 1 of the brownfield expansion, taking total capacity from 40,000 to 60,000 tons, is scheduled for completion by June 2025. Phase 2 will come on stream roughly a year later, around June 2026, with the added capacity expected to be fully utilized over three years.
- Smaller applications provide ballast: Personal care, hydrogels, detergents, and mining represent smaller but steady demand pockets, diversifying the end-use base beyond the dominant water treatment and oil recovery verticals.
Vinati Mutreja: "When we dig oil out of the oil well, they realized that the more ATBS they put in the polymer, the more efficient it becomes then they're able to extract more oil."
Antioxidants: The High-Growth Second Leg
- 70% revenue surge: The AO business posted a 70% revenue increase in FY25, driven by market expansion and product enhancements, even as Chinese and Singaporean imports created a competitive environment.
- Utilization runway is long: The plant is currently running at about 50% capacity, with a stated target to reach 90% over the next two years. This under-utilization means significant revenue growth can come from volume ramp alone before new capex is needed.
- Domestic acceptance is key: Vinati's products have been qualified by all major customers, who are keen to work with domestic suppliers. Annual or biannual contracts are expected to follow, supporting the butyl phenols and antioxidants segment toward an FY26 revenue target of INR800-850 crores, all from antioxidant growth.
- Portfolio broadening: The R&D team has developed a novel antioxidant for lubricant additives, enhancing the value proposition beyond the core polymer stabilization market.
Vinati Mutreja: "See even presently -- at present also, my AO plant is running at less than 50%, about 50% capacity. So I expect to increase the capacity utilization to 90% over the next 2 years."
VOPL: The New Subsidiary Turns the Corner
- Teething issues resolved: VOPL faced initial production challenges with its MEHQ and Guaiacol plant, resulting in a FY25 loss of roughly INR16 crores (INR12 crores depreciation, INR4 crores production and expenses). The plant is now commercially producing and selling MEHQ into both captive and merchant markets.
- FY26 revenue contribution begins: Management is targeting INR100-odd crores in revenue at about 20% capacity utilization, with new products like anisole, 4-MAP, TAA, and PTAP set for introduction across Q2 and Q3 FY26. These target polymerization inhibitors, oil filters, resins, flavors, fragrances, personal care, and pharmaceuticals.
- Captive integration deepens: MEHQ is a raw material for butylated hydroxyanisole (BHA). Once BHA is fully commercialized, captive consumption of MEHQ will absorb about 30% of total production, adding a margin-accretive downstream layer.
- Asset turn potential: On full utilization of the entire INR500 crores VOPL capex, management expects asset turns above 1:1, signaling confidence in the revenue-generating capacity of the asset base.
Portfolio Mix & Market Shifts
- Export share rebalancing: Exports have declined from 70% to 55% of revenue over 3-4 years, a structural shift driven by growing domestic demand for antioxidants (from polypropylene and polyethylene customers expanding capacities), butyl phenols, and Isobutylene used in cypermethrin.
- Segment-level divergence: While ATBS (30%) and butyl phenol (26%) posted strong FY25 growth, IBB declined 27% on demand-side challenges, and customized products remained flat. IB and HPMTBE achieved strong growth, rounding out a mixed but net-positive portfolio performance.
- R&D as the next capex signal: The team is developing three to four new products based on adjacencies: vertical, downward, and horizontal integration. Successful trials could lead to the announcement of the next leg of capex in coming quarters, though management declined to quantify R&D spend, calling it a function of allocation quality rather than absolute amount.
Financial Guardrails
- Margin stability is the anchor: Management stuck with its usual 26%-27% EBITDA margin guidance for FY26 and believes this band is sustainable over a 3-5 year period for a B2B specialty chemical business, excluding other income.
- Capex visibility: INR360-odd crores is marked for FY26 capex, covering the ATBS Phase 1 completion, ongoing VOPL product introductions, and solar capacity (32.5 MW now operational). The fixed asset increase in FY25 was driven by additions in the additives division, solar, and VOPL.
- Revenue ambition: Management projects a 20% revenue CAGR over the next three years, supported by ATBS leadership, steady butyl phenol performance, and strong antioxidant expansion.
- Expense relationship to revenue: Other expenses cannot be directly tied to revenue as a ratio, since revenue is a function of both volume and raw material prices; a decline in raw material costs would lower revenue without a proportional drop in other expenses.
Vinati Mutreja: "I think over a long term period of 3 to 5 years, 26% - 27% EBITDA margin is what is sustainable in a B2B manufacturing business specialty chemical business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| ATBS growth | Continued double-digit growth | FY26 |
| ATBS Phase 1 capacity expansion | Completion, taking capacity from 40,000 to 60,000 tons | June 2025 |
| ATBS Phase 2 capacity expansion | On stream | ~June 2026 (one year after Phase 1) |
| ATBS capacity utilization | Added capacity fully utilized | Over 3 years from completion |
| AO capacity utilization | Increase from ~50% to 90% | Over the next 2 years |
| VOPL revenue | INR100-odd crores at ~20% capacity utilization | FY26 |
| VOPL new product introductions | Anisole, 4-MAP, TAA, PTAP | Q2 and Q3 FY26 |
| Butyl phenols and antioxidants revenue | INR800-850 crores | FY26 |
| EBITDA margin | 26%-27% | FY26 |
| Revenue CAGR | 20% | Over the next 3 years |
| Next leg of capex announcement | Contingent on successful trials of 3-4 new R&D products | In coming quarters |
| FY26 capex | INR360-odd crores | FY26 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Consolidated net income (FY25) | ₹2,292 cr, +18% YoY from ₹1,939 cr |
| Consolidated EBITDA (FY25) | ₹625 cr, +23% YoY from ₹509 cr |
| Consolidated PAT (FY25) | ₹405 cr, +25% YoY from ₹323 cr |
| ATBS segment growth (FY25) | 30%, driven almost entirely by volume expansion |
| ATBS global market share | 60-65%, steady |
| Butyl phenol segment growth (FY25) | 26% |
| IBB segment growth (FY25) | -27% YoY |
| Antioxidants revenue growth (FY25) | 70% |
| Capex incurred (FY25) | ~₹400 cr, including investments in VOPL |
| Capex planned (FY26) | ~₹360 cr |
| Revenue CAGR guidance (next 3 years) | 20% |
| EBITDA margin guidance (long-term) | 26-27%, excluding other income |
| VOPL revenue guidance (FY26) | ~₹100 cr |
| Butyl phenols + antioxidants combined revenue (FY25) | ₹600 cr |
| Butyl phenols + antioxidants combined revenue guidance (FY26) | ₹800-850 cr, all growth from antioxidants |
| ATBS capacity expansion Phase 1 | 25-30% increase, on stream June 2025 |
| ATBS capex budget | ₹300 cr |
| VOPL total capex | ~₹500 cr, with ~₹250 cr yet to be done |
| VOPL FY25 loss | ₹12 cr depreciation plus ₹4 cr production and expenses |
| Revenue mix: ATBS | ~35% |
| Revenue mix: IB and HP-MTBE and other IB derivatives | ~15% |
| Revenue mix: IBB | ~11% |
| Revenue mix: Butyl phenol | 15% |
| Revenue mix: Antioxidants | 10% |
| Revenue mix: Other products | 15% |
| Export share | 55%, down from 70% three to four years ago |
| Solar capacity | 32.5 MW plant |
| Capital work in progress (as of March 2025) | ₹438 cr |
| Net fixed assets (FY25) | ₹1,723 cr, up ~₹225-235 cr YoY |
| ATBS demand split (current) | One-third each: oil and gas, water treatment, other applications |
| ATBS demand split (forward outlook) | Oil and gas 40-45%, other applications 50-55% |
| MEHQ captive consumption (once BHA fully commercialized) | ~30% of total production |
| AO plant capacity utilization (current) | ~50% |
| AO revenue (FY24) | ~₹120 cr |
| AO revenue (FY25) | ~₹210 cr+ |